[1] 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京). 中华消化杂志,2017,37:513-522.
[2] Dalle J H, Giralt S A. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant,2016,22:400-409.
[3] Valla D C, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol,2016,40:378-385.
[4] Edgar J A, Molyneux R J, Colegate S M. Pyrrolizidine Alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol,2015,28:4-20.
[5] 宋宇,樊艳华. 土三七所致肝小静脉闭塞病102例临床分析. 临床肝胆病杂志,2011,27:496-499.
[6] 朱晚林,陈韶华,陈卫星,等. 肝小静脉闭塞病50例临床分析. 中华消化杂志,2012,32:620-624.
[7] 王轶,诸葛宇征,张峰,等. 土三七致肝小静脉闭塞病治疗的单中心回顾性研究. 中华消化杂志,2016,36:811-815.
[8] Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol,2007,41 Suppl 3:S344-S351.
[9] Zhuge Y Z, Wang Y, Zhang F, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease. Liver Int,2018,38:1867-1874.
[10] Azoulay D, Castaing D, Lemoine A, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant,2000,25:987-992. |
